Kenya set to receive injectable HIV preventive drug
Health & Science
By
Mercy Kahenda
| Jul 15, 2025
Kenya is set to receive Lenacapavir, a groundbreaking HIV preventive drug that will be administered as an injection just twice a year.
This makes it the first long-acting injectable form of pre-exposure prophylaxis (PrEP), offering an alternative to the daily oral pills currently used for HIV prevention.
"The Ministry of Health through the Division of National AIDS and STI Control Programme (NASCOP), in collaboration with various partners is working to ensure avaiability of the innovative product for Kenyans by January 2026," NASCOP has announced.
READ MORE
Kenya gears up for international construction expo
PUBG Mobile deepens roots in Africa with new servers and culturally inspired features
Nyoro says govt using false narratives to hike fuel prices
E-mobility firm selected for 2025 regional climate projects platform
Gold discovery excites locals, cuts fishing pressure on Lake Victoria
Liquid, DropByDrop partner to manage non-revenue water challenges
Why local firms shy away from innovation
Economy feels the pinch as June inflows drop Sh2.1b
Centum maintains dividend payout following Sh813 million net profit
State agencies pitch nuclear energy to power industrialisation
Clinical data shows the drug has up to 99 percent efficacy in preventing HIV transmission.
“Lenacapavir is highly effective and long-lasting," added NASCOP.
The injection is administered under the skin in the abdominal area (stomach) by a healthcare provider and is designed to be discreet, convenient, and stigma-free.
Kenya is expected to receive the drug with procurement supported by the Global Fund and other partners.
The rollout will be coordinated by the Ministry of Health through NASCOP, in collaboration with partner organisations.
“This is a major milestone in our efforts to end HIV/AIDS by 2030,” NASCOP noted.
The official launch of Lenacapavir was announced following an agreement signed between the Global Fund and Gilead Sciences.
Alongside Kenya, other high HIV burden countries set to benefit from the new injectable PrEP include Botswana, Eswatini, Ethiopia, Lesotho, Malawi, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe.